Waltham, Mass., Feb. 13, 2018— Sobi, a pioneering international biopharmaceutical company dedicated to rare and difficult-to-treat diseases, announced today the appointment of Linea Aspesi as vice president of human resources for North America.
Aspesi has 20 years’ experience in human resources, which she will apply to support Sobi’s growth in North America. She will be responsible for talent acquisition, management and retention; performance management; total rewards; organizational design; employee relations; and collaboration with Sobi’s global human resources function.
Aspesi most recently served as head of human resources, Industrial Affairs in the U.S. for Sanofi, where she was responsible for shaping, driving and executing talent strategies and helping to transform the 3,000-employee Industrial Affairs North American organization. She also previously supported the Sanofi Genzyme commercial business unit, gaining experience in the rare disease field. Prior to that she held multiple positions of increasing responsibility with the Sanofi human resources department, receiving four promotions in six years. Before joining Sanofi, Aspesi held HR positions at multiple organizations including UMass Memorial Medical Center, Partners Healthcare System Inc., Benchmarking Partners Inc., HealthSouth and others. She currently serves on the board of directors for Partnerships for a Skilled Workforce and for Seaglass Village.
“Sobi is committed to growing our footprint in North America, and Linea’s experience both recruiting and developing teams will be critical to support this effort,” said Rami Levin, President of Sobi in North America.
“The Sobi team is passionate about serving patients, and that passion – combined with the depth of subject matter expertise each employee brings to the table – provides a strong base on which to develop and grow this organization,” said Aspesi. “I look forward to supporting Sobi in achieving its vision of becoming a leader in the rare disease field.”
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about 760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com and www.sobi-northamerica.com.
For more information please contact: